Item 1.01 Entry into a Material Definitive Agreement. On December 31, 2021, Cumberland Pharmaceuticals Inc. (the "Company" or "Cumberland") entered into an amendment to expand the capital available on its bank line of credit to $20 million. The Company has previously used proceeds from the line to fund acquisitions, working capital and general corporate purposes. The Amendment was to the Company's Revolving Credit Loan Agreement with Pinnacle Bank and increased the principal available to $20 million. As of December 31, 2021, the interest rate for funds drawn on the facility is 1.85% - 2.60% depending on the funded debt to EBITDA ratio. Borrowings under the line of credit are collateralized by the Company's assets.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses